RE: Best case scenario8 Jan 2021 08:22
Impossible question to accurately answer, but taking the language and comparisons from former CEO Dan Gooding, probably £1 to £2 per share when the eventual sale of company is made.
Interim CEO Chris Blackwell was drawn on making on comparisons
Current Part Time CEO Anne Brindley has been equal mute on this front, on her appoint she said;
"I am delighted to have accepted the role of CEO of Nuformix at this important time for the Company. I look forward to driving the business strategy and achieving the Company's objectives. Having worked in the pharma industry for over 30 years, I can see that Nuformix has assets and technology that have great potential and I intend to work with the Board to take these forward in development."
Been invested in Leveritt and now NFX for four years and am really wondering if any value can be attributed to what they do.
On the plus side we have some very reputable people on board such as Chris Blackwell who see's large potential in our products, but at the end of the day its is nearly impossible put a value on this!